Decitabine/cedazuridine (acute myeloid leukaemia) – Benefit assessment according to §35a Social Code Book V

Report documents

1. Extract of dossier assessment

   Decitabine/cedazuridine (acute myeloid leukaemia) – Benefit assessment according to §35a Social Code Book V

   published on

   03.06.2024

   Document type

   PDF document, 275 kB, EN, not accessible

   DOI-Link

   https://doi.org/10.60584/A24-29_en

   Download file : Extract of dossier assessment (PDF document, 275 kB, EN, not accessible)
2. Dossier assessment

   Decitabine/cedazuridine (acute myeloid leukaemia) – Benefit assessment according to §35a Social Code Book V

   published on

   03.06.2024

   Document type

   PDF document, 531 kB, DE, not accessible

   DOI-Link

   https://doi.org/10.60584/A24-29

   Download file : Dossier assessment (PDF document, 531 kB, DE, not accessible)

Dossier assessment

Project details

Project no.

A24-29

Commission

Commission awarded on 04.03.2024 by the Federal Joint Committee (GBA).

Report type

Dossier assessment

Status

Commission completed

Department/Division

Drug Assessment

Topic

Cancer

Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

DOI

https://doi.org/10.60584/A24-29_en

Connected Projects

1. Dossier assessment

   Decitabine/cedazuridine (AML) – Benefit assessment according to §35a Social Code Book V

   Project no.

   A26-85

   Last updated

   15.10.2026

   Status: Commission completed